Todays price rise, is probably associated with the announcement in Medical news Today: BioDiem To Commence Diabetic Blindness Trial With BDM-E Treatment.
Australian biopharmaceutical development company BioDiem Ltd (ASX: BDM) announced today it has received regulatory approval to commence a phase I/II clinical trial for its peptide BDM-E in patients with diabetic macula oedema, a leading cause of blindness.
Todays price rise, is probably associated with the announcement...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $31.26M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 448 | 2.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.4¢ | 388415 | 4 |
View Market Depth
| Last trade - 10.02am 15/09/2025 (20 minute delay) ? |
| BDM (ASX) Chart |
Day chart unavailable